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We provide evidence that the androgen receptor (AR)
can promote nuclear translocation of -catenin in LNCaP
and PC3 prostate cancer cells. Using AR-expressing cells
(LNCaP) and non-AR-expressing cells (PC3) we showed by
time course cell fractionation that the AR can shuttle
-catenin into the nucleus when exposed to exogenous
androgen. Cells exposed to the synthetic androgen, R1881,
show distinct, punctate, nuclear co-localization of the AR
and -catenin. We further showed that the AR does not
interact with adenomatous polyposis coli or glycogen syn-
thase kinase-3 and, therefore, conclude that androgen-
mediated transport of -catenin occurs through a distinct
pathway. The minimal necessary components of the AR
and -catenin required for binding nuclear accumulation
of -catenin nuclear import appears to be the DNA/ligand
binding regions and the Armadillo repeats of -catenin.
We also employed a novel DNA binding assay to illustrate
that -catenin has the capacity to bind to the probasin
promoter in an AR-dependent manner. The physiological
relevance of AR-mediated transport of -catenin and
binding to an AR promoter appeared to be a substantial
increase in AR transcriptional reporter activity. AR-
mediated import represents a novel mode of nuclear ac-
cumulation of -catenin.
The androgen receptor (AR)1 has a fundamental role in de-
velopment and differentiation of androgen-sensitive tissue but
also has an important role in prostate cancer (1). Proliferation
of prostatic epithelium is dependent on the uptake of andro-
gens from the serum through the cell membrane, binding to the
cognate steroid receptors, and translocation to the nucleus
leading to activation of transcription (2, 3) of downstream
genes (4). Structurally, the AR belongs to a superfamily of
ligand-activated transcription factors composed of a highly con-
served DNA binding domain (ARDBD) and a moderately con-
served ligand binding domain (ARLBD), while containing an
N-terminal domain (ARNt), which is least conserved (5–7). The
ARNt contains a ligand-independent transcriptional activating
function whereas the ARCt contains one that is ligand-depend-
ent (8). The ligand binding domain of nuclear receptors interact
with a variety of other proteins following ligand binding (9),
which has the potential to augment or modulate transcrip-
tional response. The transcriptional activity of the AR is largely
determined by the presence or absence of other co-factors,
including co-activators, which enhance AR activity, and co-
repressors, which repress AR activity. Examples of previously
identified co-activating molecules of the AR include CBP,
SRC1, and TIF-2 (10–12).
There is strong documentation to suggest steroid receptor
shuttling upon exposure to the cognate ligand. Such studies
have pertained to the AR (13–16), glucocorticoid receptor (GR)
(17), estrogen receptor (ER) (19), mineralocorticoid receptor
(20), and thyroid receptor (TR) (21). These receptors show a
certain degree of trafficking either to or from the nucleus but
also in a subnuclear fashion. Those that show a strong migra-
tion to the nucleus upon exposure to ligand are termed “trans-
locating receptors” and can be contrasted with receptors that
are constitutively nuclear (4). The ER shows expression that is
mainly nuclear in the absence of ligand (22), whereas the AR
and GR show a distribution that is both cytoplasmic and nu-
clear (23, 22). Curiously, there are varying reports as to rela-
tive abundance of AR in the cytoplasm (24) and in the nucleus
(6) in many cell types. Upon receptor stimulation by DHT, or
potent analogues of DHT, including R1881, the AR will disso-
ciate from heat-shock proteins, translocate to the nucleus, and
form transcriptionally active DNA-protein complexes (4). In
general, this two-step model for steroid hormone receptor ac-
tion can be applied to the AR and GR whereby the unliganded
receptor is localized in the cytoplasm and upon ligand binding
undergoes conformational change that permits translocation to
the nucleus. This homodimerization leads to initiation of target
gene regulation (15). Within the nucleus most members of the
receptor superfamily form focal accumulations within the nu-
cleus in the presence of ligand (4).
Proteins that are carried or shuttled with steroid receptors
into the nucleus have not been thoroughly explored. Therefore,
with the ability of the AR to translocate to the nucleus, we
hypothesize that the AR could co-traffic other molecules to the
nucleus. Examples of this phenomenon are few if any. Cyto-
plasmic to nuclear and subnuclear trafficking could allow for
formation of multiprotein-DNA complexes and AR transcrip-
tional activation (15). Given the documented ligand-dependent
relationship between the AR and -catenin (25), we hypothe-
size that -catenin could be part of a complex that translocates
to the nucleus as a pre-requisite to forming transcriptionally
active, nuclear complexes.
-Catenin is a multifunctional protein. Specifically, it plays a
central role in cell adhesion by its association with E-cadherin
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and the actin cytoskeleton via linking to -catenin (26, 27). In
addition to its role at adherens junctions, -catenin is a major
component in the Wnt/Wingless signaling pathway. This well-
studied pathway is important both in normal tissue develop-
ment and differentiation (28) as well as in oncogenesis (27). In
the absence of Wnt/Wingless signaling, -catenin is found
mainly at cell junctions but also associates with cytoplasmic
proteins, including adenomatous polyposis coli (APC) (29); gly-
cogen synthase kinase-3 (GSK-3) (30), and axin (30). When
-catenin accumulates, it is phosphorylated by GSK-3 and tar-
geted for ubiquitination by the proteasome complex (30). Stim-
ulation of the Wnt/Wingless pathway inhibits GSK-3 and al-
lows for accumulation of hypo-phosphorylated -catenin in the
cytoplasm. Stabilized -catenin can then translocate to the
nucleus, with Lef, and interact with the Lef/Tcf family to stim-
ulate gene expression of cell cycle-associated proteins. Some of
the targeted genes, that are thought to be regulated by a
-catenin-Tcf complex, include c-myc, tcf-1, and cyclin D1 (31).
An intriguing feature of Wnt signaling is the manner in
which -catenin is actively translocated to the nucleus. Al-
though -catenin does not have a nuclear localization signal
(32), APC (adenomatous polyposis coli) can act as a nuclear-
cytoplasmic shuttling protein (32). Such studies have shown
that alteration of the amino nuclear export sequence on APC
could accumulate nuclear -catenin and concluded that APC
can shuttle between the nucleus and cytoplasm while directing
-catenin to functionally important locations. APC also con-
tains two nuclear localization signals that are necessary for
optimal nuclear APC activity (33) and likely for its tumor
suppressor function. Recently, studies have shown that nuclear
export of -catenin can occur independent of the CRM1 export
protein and suggested that there could be alternative pathways
associated with -catenin transport (34). Previous studies have
also shown that -catenin can localize to the nucleus independ-
ent of the shuttling protein Ran (35).
Little is known about the functional contribution of the re-
cently identified ligand-dependent interaction between -cate-
nin and the AR. In this study, 1) we used confocal microscopy
and a novel DNA binding assay to provide evidence that -cate-
nin binds in an AR ligand-dependent manner, via the AR, to an
androgen-regulated promoter; 2) we defined the domains of the
AR and -catenin as they related to protein interactions and
related this to transcriptional activity; 3) we demonstrated that
AR can translocate -catenin to the nucleus in an AR ligand-
dependent fashion as a distinct pathway that is independent
of APC; 4) finally, we identified the structural components of
the AR and -catenin that are necessary and sufficient for
co-translocation.
EXPERIMENTAL PROCEDURES
Cell Culture—PC3 and HeLa FLAG-AR cells were cultured in Dul-
becco’s modified Eagle’s medium containing 5% FBS and LNCaP cells
in RPMI media containing 5% FBS. Cells were transiently transfected
in serum-free media for 6–20 h with the following expression cDNAs:
(WT HA-tagged), -catenin (WT myc-tagged), -catenin (Nt), -catenin
(Arm repeats HA-tagged), -catenin (Nt/Ct HA-tagged), rat AR (WT),
AR (Nt), AR (Nt/LBD), AR (DBD), AR (DBD/LBD), GR (WT), TR (WT),
and RAR (WT). Cells were treated with 10 nM steroid receptor ligand in
5% dextran/charcoal-stripped serum. Stable AR FLAG-tagged HeLa
cells were kindly donated by Dr. Michael Carey (UCLA School of
Medicine).
Plasmids—AR luciferase reporter, AR, and GR expression constructs
were constructed as previously described (Snoek et al. (8)). -catenin
cDNAs were obtained both from Dr. Berry Gumbiner (Memorial Sloan-
Kettering Cancer Center, New York, NY) and Dr. Randall Moon
(Howard Hughes Medical Institute, University of Washington). All
remaining receptor expression constructs were obtained from Dr. Ro-
nald Evans (Salk Institute, La Jolla, CA).
Immunofluorescence—Cells were grown in 5% FBS in RPMI on glass
coverslips, fixed in cold methanol for 10 min, and air-dried. Cells were
reconstituted in 4% normal serum in 0.1% Tween 20/phosphate-buff-
ered saline for 20 min. Primary polyclonal -catenin (sc-8199) antibod-
ies and monoclonal AR (DNA binding domain, 15071A) antibodies were
used at a dilution of 1:100 and incubated for 1–2 h at 37 °C followed by
3  10-min washes. Secondary antibodies conjugated to fluorophores
were used at a 1:100 dilution and were incubated for 1 h at 37 °C
followed by 3  10-min washes. Coverslips were mounted with mount-
ing media containing DAPI (Vector Laboratory) on glass slides. Confo-
cal microscopy images were obtained used a Bio-Rad 1024 system and
were digitally compiled using IMAGE software (National Institutes of
Health).
Cell Fractionation and Time Course Study—Subsequent to transfec-
tion and a least 12-h growth in charcoal-stripped serum, LNCaP, PC3,
and HeLa FLAG-AR cells were treated with 10 nM ligand for up to 60
min. Prior to harvest, cells were washed once in cold PBS and separated
into cytoplasmic and nuclear fractions using the Nuclear and Cytoplas-
mic Extraction Reagent (Pierce) at 10-min intervals. Fractions were
assayed for total protein using the BCA protein assay (Pierce, 23223).
Western Blotting and Immunoprecipitation—Subconfluent cell cul-
tures were washed with PBS, sheared with a 30-gauge needle, and
solubilized with Nonidet P-40 lysis buffer (0.5% Nonidet-P-40, 150 nM
NaCl, 50 mM Tris, pH 8.0) on ice for 30 min with the addition of a
protease inhibitor mixture (Roche Molecular Biochemicals, 1697498).
Cell lysates were centrifuged at 15,000 rpm for 10 min, standardized for
total protein, and separated by SDS-PAGE. Immunoprecipitations were
carried out overnight at 4 °C with up to 5 g of precipitation antibody.
During the last 60 min of incubation 30 l of Protein A/G-Sepharose
beads (Santa Cruz Biotechnology, sc-2003) were added. Immune com-
plexes were washed four to five times in cold lysis buffer containing
inhibitors. After boiling in Laemmli sample buffer, samples were sep-
arated by SDS-PAGE and the proteins were transferred onto a polyvi-
nylidene difluoride membrane (Amersham Biosciences, Inc.). Mem-
branes were blocked with 5% nonfat milk in TPBS (0.05% Tween 20 in
PBS) for 1 h and then incubated for 1–2 h at room temperature with
primary antibodies, either actin (Sigma-Aldrich, A2066), Histone
(Chemicon International), -catenin (Transduction Laboratory,
C19220; Santa Cruz, sc-8199), E-Cadherin (Santa Cruz, sc-1500),
GSK-3 (Transduction Laboratory, G22320), N-terminal Androgen Re-
ceptor (ABR, PA1–111A), DNA binding domain Androgen Receptor (BD
PharMingen, 15071A), or C-terminal domain Androgen Receptor (San-
ta Cruz, sc-815). Detection was achieved with either anti-mouse-horse-
radish peroxidase (Santa Cruz, sc-2031) or anti-rabbit-horseradish per-
oxidase (Santa Cruz, sc-2030) and ECL Western blotting detection
agents (Amersham Biosciences, Inc., RPN 2106).
In Vitro Translation—Plasmid cDNA was transcribed and translated
in vitro using the rabbit reticulocyte lysate TnT (Promega) system. A
standard reaction was used consisting of 40 l of TnT Quick Master
(SP6 or T7 promoter), 2 l of cold 2 mM methionine (1000 Ci/mol at 10
mCi/ml), 1–2 g of plasmid DNA made up to a final volume of 50 l with
nuclease-free water. Reactions were incubated at 30 °C for 90 min and
either used immediately for binding reactions or stored at 20 °C. The
efficiency of in vitro translation reactions were assessed by monitoring
[35S]methionine incorporation by SDS-PAGE and radiography follow-
ing equilibration in ENHANCE (Cat. NEF981, PerkinElmer Life Sci-
ences). Gels were washed 2  10 min with dH2O, dried, and exposed to
radiographic film.
GST-Pull Downs—Recombinant proteins were labeled with [35S]me-
thionine (Promega TnT) in a volume of 50 l. GST-bound beads were
equilibrated with binding buffer (20 mM HEPES, pH 7.6, 150 mM KCl,
5 mM MgCl2, 1 mM EDTA, 0.05% Nonidet P-40, and protease inhibitors)
and incubated with lysate for 2 h at 4 °C. Complexes were washed 4
with 1 ml of cold binding buffer, boiled in Laemmli sample buffer, and
separated by SDS-PAGE. Gels were enhanced, dried, and exposed to
film.
Acrydite Capture of DNA-binding Complexes—The ACDC assay (36)
was carried out by incubating recombinant His-tag androgen receptor
DNA binding domain (His-tag ARDBD) without DNA or with NF-1
acrydite binding sites or ARE acrydite binding sites (ARE-ac). The
nuclear factor-1 (NF-1) acrydite served as a negative binding control.
Binding reactions were polymerized in the well of a 5% polyacrylamide
acrydite gel, run on a 15% SDS-PAGE and probed with anti His-tag
antibody. LNCaP nuclear extracts (NE) treated with 10 nM R1881 were
incubated with ARE-ac and polymerized inside the well of a 5% poly-
acrylamide gel. After electrophoresis, the specifically bound protein was
extracted from the acrydite gel, separated by SDS-PAGE (8.5%), and
probed with an anti-AR antibody (DBD epitope). NE were incubated
without DNA or with acrydite probasin (P-ac) promoter (286 to 28)
or the pBluescript acrydite multiple cloning site (MCS-ac) created by
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PCR amplification using specific primers with a 5-acrydite moiety
attached.
Luciferase Reporter Assays—PC3 and LNCaP cells were plated in
6-well dishes and incubated overnight at 37 °C. Cells were transfected
with a total of no more than 4 g of DNA per well for 8–16 h using
LipofectAMINE (Invitrogen) according to the manufacturer’s protocol.
After transfection, cells were incubated in charcoal-stripped serum
containing 10 nM R1881, dexamethasone, estradiol, all-trans-retinoic
acid, or tri-iodothyronine for at least 16 h. All assays were carried in at
least triplicate and evaluated using the Dual Luciferase Reporter sys-
tem (Promega).
RESULTS
Ligand-dependent Co-localization of -Catenin and AR—The
localization of AR (Fig. 1, ai) and -catenin (aii) was viewed
with confocal microscopy using antibodies to the DNA binding
domain of the AR and Arm repeats/Ct portion of -catenin in
fixed LNCaP cells that were treated with and without R1881
for 60 min (Fig. 1). Images captured by confocal microscopy and
compiled in images analysis software suggest that in the ab-
sence of androgen the AR (bi) stained diffusely throughout the
cell, whereas -catenin staining (bii) was predominately found
at cell borders, diffusely in the cytoplasm, and within the
nucleus. In the presence of ligand we observed a specific, punc-
tate staining pattern of AR (ai), which was strongly nuclear.
-Catenin also showed nuclear localization (aii) in cells upon
ligand addition and co-localized in many instances with AR
(arrowheads) whereas in some instances it did not (arrows).
Levels of -catenin at cell borders were not observed to change
in response to AR ligand, whereas cytoplasmic levels appeared
to decrease moderately. Nuclei were stained using DAPI (Fig.
1, aiv and biv).
ARDBD/LBD Interacts with the -Catenin Arm Repeats—As a
prerequisite to assessing the trafficking properties of the AR,
we determined the relative affinity of binding between the AR
and -catenin. To do this we used recombinant AR proteins,
including ARNt, ARDBD/LBD, ARDBD, and ARNt/DBD (Fig. 2a).
-Catenin 35S-labeled deletion mutants included Nt-(1–140),
Arm repeats-(140–664), and Ct-(664–781) domains (Fig. 2b)
translated in vitro from Xenopus expression constructs. Al-
though relatively weak interactions were detected between the
-CatNt, or -CatCt, and any portion of the AR (only slightly
greater than the GST-negative control), strong interactions
were detected between the -catenin Arm repeats and AR (Fig.
2c). The Arm repeats showed moderate interactions with the
ARDBD but increased affinity with the ARDBD/LBD suggesting a
role both for the DBD and LBD in binding AR and -catenin.
Despite the differences detected in our physical mapping using
our recombinant truncations we were unable to detect a signif-
icant difference (10%) between AR-GST/-catenin binding
affinity in the presence or absence of ligand. We have attrib-
uted this to potential masking of interaction sites by chaperone
proteins in the cell in absence of ligand, which is not present in
the recombinant system. In general, these data support tran-
scriptional assays, immunoprecipitation studies, and shuttling
time courses.
Ligand-bound AR Promotes Nuclear Translocation of Cyto-
solic -Catenin—To determine if -catenin was able to trans-
locate to the nucleus in an androgen-dependent manner, we
performed a series of cell fractionations on LNCaP cells and
HeLa-FLAG AR cells over a time course of androgen exposure
(Fig. 3). Cytoplasmic and nuclear compartments were effi-
ciently separated as determined by probing nuclear fractions
for pan-Cadherin and probing cytoplasmic fractions for total
histone (Fig. 3A). The low levels of pan-Cadherin in nuclear
fractions and histone in the cytosol suggested an efficient sep-
aration of cellular compartments. We further demonstrated
equal total protein loads through a time course by assessing
total cytosolic actin and nuclear histone (Fig. 3A). Non-trans-
fected LNCaP cells that were treated with R1881 and were
fractionated into cytoplasmic and nuclear compartments at
10-min intervals over 60 min (10, 20, 30, 40, 50, and 60 min)
showed a moderate accumulation of endogenous, nuclear
-catenin (Fig. 3B). We observed a similar increase in nuclear
AR. Densitometry evaluation of nuclear accumulation of AR
and -catenin suggest a similar rate of increase. Loading con-
trols (actin) remained constant (Fig. 3Bii). A less noticeable
decrease in cytosolic -catenin was observed when compared
with changes in nuclear -catenin levels. This is likely ac-
counted for by the large amount of -catenin that remained
stationary; that is, that does not migrate upon addition of AR
ligand. Interestingly, the shift in -catenin found in cytosolic
and nuclear compartments was considerably more noticeable
in LNCaP cells, which were transiently transfected with tagged
expression constructs for -catenin (Fig. 3C). Specifically, by
transfecting LNCaP cells with either HA-tagged and myc-
tagged -catenin constructs, we observed a greater amount of
nuclear accumulation of the de novo synthesized -catenin as
compared with non-transfected cells. Densitometry analysis
(Fig. 3Cii) showed a similar trend in nuclear accumulation of
-catenin and illustrated a plateau at 50-min post-ligand ad-
dition suggesting a decreased rate of nuclear import. We fur-
ther chose to consider whether AR-dependent movement of
-catenin could occur using other AR ligands, including the
physiological androgen, DHT. DHT, like its analogue, R1881,
promoted nuclear accumulation of both the AR and -catenin
although to a slightly lesser extent than with R1881 (data not
shown). We next investigated whether other non-prostate can-
FIG. 1. Localization of the AR (ai) and -catenin (aii) in meth-
anol-fixed LNCaP cells treated with 10 nM R1881 for 60 min
viewed with confocal laser microscopy. In the absence of R1881,
AR staining (bi) appears diffuse and throughout the cytoplasm whereas
that for -catenin (bii) is localized at the cell membrane, in the cytosol,
and in the nucleus. When serial images collected by confocal microscopy
were digitally compiled, the distribution of the AR appeared punctate
and nuclear (ai). Similarly, -catenin (aii) showed a punctate pattern
that co-localized in some instances (arrowheads) whereas in others
(arrows) did not (overlay  aiii, biii; DAPI  aiv, biv) (bar  5 m).
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cer cell lines, including stably AR-FLAG-transfected HeLa cells
could mediate AR-mediated -catenin nuclear translocation. To
do this we isolated cell fractions at 0 and 60 min post-ligand
addition and immunoprecipitated AR, FLAG, and -catenin
(Fig. 3D). We observed a trend of nuclear accumulation of
-catenin similar to that in LNCaP cells, although -catenin
movement from the cytosol was not as apparent as neither was
the overall movement of the FLAG-AR. We further assessed
the relative amounts of nuclear and cytosolic AR-associated
-catenin in these cells by immunoprecipitation of FLAG
tagged AR (Fig. 3D). In the absence of androgen, there were
greater amounts AR in the cytosol as judged by anti-FLAG and
anti-AR antibodies whereas greater amounts in the nuclear
fractions of cells were treated with ligand. We found detectable
-catenin with AR and FLAG-AR immunoprecipitates in the
absence of androgen confirming the presence of a constitutive
interaction as observed with LNCaP immunoprecipitations
(Fig. 3D). We further demonstrated that there were detectable
amounts of the AR/-catenin complex in nuclei without andro-
gen but substantially higher in its presence (Fig. 3D).
The ARDBD/LBD Is Necessary and Sufficient for Nuclear
Translocation of -Catenin in PC3 Cells—Having found evi-
dence that the AR can translocate -catenin to the nucleus in
LNCaP and HeLa cells, we chose to ascertain whether other
nuclear receptors have this capability in PC3 prostate cancer
cells. To do this we used a prostate cancer cell line that dose not
express the androgen receptor. When PC3 cells were tran-
siently transfected with RAR (Fig. 4A), ER (Fig. 4B), GR (Fig.
4C), TR (Fig. 4D), or -catenin (HA-tag) we observed an inabil-
ity to move -catenin to the nucleus with ligand exposure.
FIG. 2. a, structural maps of recombi-
nant AR deletion truncations (WT, Nt,
DBD/LBD, DBD, Nt/DBD); b, in vitro
translated -catenin/35S deletion trunca-
tions (WT, Arm repeats, Nt, and Ct com-
ponents). Relative to the total input the
highest affinity of interaction was de-
tected between the -catenin/35S Arm re-
peats and the ARDBD/LBD (c). Interest-
ingly, there was little difference (10%)
in the efficiency of binding reactions with
or without the presence of AR ligand (data
not shown).
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FIG. 3. LNCaP cell nuclear translocation of -catenin in the presence AR ligands over a time course of 60 min (10-, 20-, 30-, 40-, 50-,
and 60-min intervals). A, cells were fractionated into cytoplasmic and nuclear components and assessed for relative amounts of AR and -catenin.
Clean separation was assessed by probing cytoplasmic fractions for histone and nuclear fractions for cadherins. Total protein loads (A) were
assessed by the abundance of actin and histone in cytoplasmic and nuclear fractions, respectively. LNCaP nuclear translocation of endogenous
-catenin (Bi) and accompanying densitometry (Bii). HA- and myc-tagged forms of -catenin. Translocation of HA- and myc-tagged -catenin (Ci)
in LNCaP cells and accompanying densitometry (Cii). Stable AR-FLAG-tagged HeLa cells (D) show a moderate movement of AR and -catenin from
a cytoplasmic fraction (0 min) when compared with R1881 treated fractions (60 min).
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Although the GR shows an ability to translocate to the nucleus
upon exposure to ligand, co-trafficking with -catenin was not
detected in this cell line despite minor fluctuation in GR cellu-
lar levels.
With -catenin translocation being detected most pro-
nounced with the AR we chose to assess -catenin movement
using various AR deletion mutants (Fig. 4, E–Hi). In PC3 cells
the empty, control expression vector (PRC/CMV) and that of
the amino terminus (Nt) of the AR showed little ability to move
-catenin to the nucleus (Fig. 4F). However, constructs ex-
pressing the ARNt/DBD showed a more prominent cellular ex-
pression but did not show ligand-dependent changes in nuclear
distribution of itself or -catenin as a function of ligand (Fig.
4G). When cells were transfected with constructs expressing
both the ARLBD and the ARDBD ligand-dependent translocation
of -catenin was readily apparent (Fig. 4Hi). This indicated to
us the necessity of both the DNA binding domain and the
ligand binding domain of the AR for efficient -catenin nuclear
translocation. Densitometry indicated a coincident movement
between the AR and -catenin. Additionally, accumulation in
PC3 cells was similar to that in LNCaPs in that both appeared
to plateau at 50–60 min post-ligand addition. We further dem-
onstrated that the Arm repeats are both necessary and suffi-
cient for AR-dependent nuclear translocation of Catenin. Con-
structs expressing the Nt and Ct components of Catenin
showed little, if any, fluctuation between compartments
whereas the Arm repeats showed accumulation to the nucleus
over 60 min (Fig. 4I).
AR-mediated Translocation of -Catenin Is Distinct from
APC/GSK3—To determine if AR-mediated import of -catenin
was a distinct pathway, we assessed whether the AR had the
ability to interact with APC and GSK3 in LNCaPs (whole cell
lysates) treated with and without R1881. As controls we probed
AR immunoprecipitations for AR (Fig. 5a) and -catenin (Fig.
5b). We detected little fluctuation in AR levels as a function of
hormone treatment but observed a ligand sensitive interaction
between AR and -catenin, which is more -catenin-associated
with AR in the presence of androgen. Immunoprecipitated
GSK3 showed a distinct band at about 45 kDa but was not
detected in AR immunoprecipitates. Although APC immuno-
precipitates showed some degradation at 180 and 200 kDa,
major species were detected at 300 kDa. These immunoprecipi-
tates also did not contain detectable AR either with or without
ligand.
-Catenin and the AR Complex Directly on the Probasin
Promoter—Acrydite experiments operate on the premise that
protein specifically bound to a DNA sequence during a binding
reaction will remain intact after being exposed to a electro-
phoretic current. Such species were then denatured and sepa-
rated by SDS-PAGE. Our results showed that the androgen
receptor from nuclear receptor extracts treated with R1881
bound specifically to ARE-acrydite (ARE-ac) PCR products
(Fig. 6). This was verified by the presence of the HIS-tag
component of the ARDBD in the elution from the ARE-ac bind-
ing reaction (Fig. 6a). AR antibodies also reacted strongly with
androgen response elements and with only a small amount of
nonspecific binding with negative controls, including a binding
reaction for NF-1 and binding reactions without DNA (Fig.
6bi). Fig. 6bii indicates the extent of recovery of the androgen
receptor in nuclear extract binding reactions and was meas-
ured by comparing the reactivity with antibodies toward the
DNA binding region of the AR with that which is specifically
bound to the ARE-ac DNA sequence. Fig. 6c suggests that,
when binding reactions were probed for -catenin using a pro-
moter sequence known to contain four cooperative ARE (286/
28), high amounts of -catenin were detected. Only small
amounts of -catenin were detected in negative control binding
reactions, including the multiple cloning site-acrydite PCR re-
action (MCS-ac) or binding reactions without DNA. These data
strongly support the presence of a ligand-dependent transcrip-
tionally active AR/-catenin complex directly associated with
the probasin promoter. Treating LNCaP nuclear extracts with
2 M NaCl and separating the non-extracted nuclear components
by SDS-PAGE show a greater amount of both AR and -catenin
retained in the presence of ligand (Fig. 6d). This suggests that
both are incorporated into the nuclear matrix to a greater
extent in the presence of ligand.
The Arm Repeats and ARLBD Are Sufficient for Ligand-de-
pendent Interaction of AR and -Catenin—Using PC3 cells we
sought to evaluate the various components of the AR and
-catenin that were necessary for ligand-dependent transcrip-
tional activation. To do this, we transfected AR and -catenin
truncations into PC3 cells and monitored ARR3-Luc activity as
a function of increasing -catenin. We observed that AR trun-
cations containing only Nt provided little transcriptional re-
sponse whereas AR constructs expressing the Nt plus the DBD
showed constitutive activation and some augmentation by
-catenin. Cells transfected with both the LBD and the DBD
showed a dose- and ligand-dependent transcriptional response
to increasing -catenin (Fig. 7A). This suggests the require-
ment of the ARLBD for ligand-dependent co-activation of the AR
by -catenin as well as for AR-mediated translocation of -cate-
nin. Cells transfected with only the ARNt or control vector
(PRC/CMV) showed relatively little transcriptional activity.
Transfections using constructs coding for only the Arm repeats
(Fig. 7B) were still able to enhance the AR transcriptional
response using the ARR3-Luc reporter in a ligand-dependent
manner but not to the same extent as the full-length -catenin.
Deletion of the Arms diminishes the ability of -catenin to
augment AR transcription considerably.
DISCUSSION
Androgen receptor trafficking of -catenin is a particularly
attractive hypothesis for several reasons. First, -catenin does
not have an identified nuclear localization signal making it
dependent upon other chaperone molecules for nuclear import.
Second, the nuclear interactions between the AR and -catenin
are ligand sensitive. Third, AR-mediated transport of -catenin
appears to be distinct from APC transport of -catenin. Fourth,
transcriptional activity of AR promoters is augmented with
increased levels of transfected -catenin when in the presence
of ligand.
In this study, we provided evidence for a novel and distinct
mechanism by which -catenin can enter the nucleus of AR
expressing cancer cell lines. We showed that upon exposure to
androgen the AR is capable of shuttling -catenin to the nu-
cleus, thus providing a means by which -catenin can augment
the transcriptional activity of AR reporters. This mode of im-
port appears to be functionally independent of the -catenin
transporter protein, APC. Immunofluorescence studies
strongly suggest co-localization of endogenous AR and -cate-
nin at punctate complexes in the nucleus of LNCaP prostate
cancer cells in the presence of R1881. Co-immunoprecipitation
studies suggest a cytosolic AR/-catenin interaction but not
with APC or GSK3. Further evidence for an AR/-catenin com-
plex that can directly bind to an AR-regulated promoter was
provided using a novel DNA binding assay. Finally, we pro-
vided evidence that the -catenin Armadillo repeats, and the
ARDBD/LBD sequence is sufficient for ligand-dependent nuclear
translocation and transcriptional activation.
AR and -Catenin Can Co-localize at Transcriptionally Ac-
tive, Multiprotein Nuclear Complexes—Using confocal laser mi-
croscopy we showed that -catenin can co-localize with AR
AR Promotes Nuclear Translocation of -Catenin17938
 at Queensland Univ of Technology (CAUL) on M
ay 14, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
FIG. 4. PC3 cells transfected with full-length -catenin (HA-tagged) with either (A) RAR, (B) ER, (C) GR, or (D) TR. Receptor-
mediated translocation of -catenin in PC3 cells transiently transfected with (E) no AR (PRC/CMV vector), (F) ARNt, (G) ARNt/DBD, (Hi) ARDBD/LBD,
and (Hii) accompanying densitometry. Time course examination of LNCaP cells transfected with ARWT and -catenin truncations, including that
with the amino and carboxyl components and that with only the Arm repeats.
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using antibodies specific for the DNA binding region of the
receptor in the presence of androgen. The localization of other
steroid receptors in the nucleus has been described, and, as
with the GR (17), ER (37), and TR (38), the AR shows a distinct
punctate appearance upon exposure to ligand. Although the
RAR and TR do not show substantial migration to the nucleus
FIG. 5. Assessment of interaction between AR and Wnt components including -catenin (a), GSK3 (b), and APC (c) in LNCaP cells
treated with () and without () R1881. Although AR interacted with -catenin in a ligand-sensitive manner, an interaction with GSK3 and
APC was not detected. Control immunoprecipitations for AR (a) and APC (c) showed species at 120 and 300 kDa, respectively.
FIG. 6. Specific retention of pro-
teins to androgen-regulated pro-
moter regions using the acrydite cap-
ture of DNA complexes (ACDC)
method. a, retention of the His-tag
ARDBD was observed only for the specific
ARE-ac binding site not for the non-cog-
nate N1-ac binding or in the absence of
DNA. bi, The ACDC method was used to
capture the full-length AR and a proteo-
lytic cleavage product of the AR that
binds DNA. c, the ACDC assay was used
to capture -catenin from LNCaP nuclear
extracts treated with 10 nM R1881. Nu-
clear extracts were incubated without
DNA or with acrydite probasin (P-ac)
promoter (286 to 28) or the pBlue-
script acrydite multiple cloning site
(MCS-ac). Retention of -catenin for the
AR-containing LNCaP NE was observed
only for P-ac, which contains four known
AREs. No retention was observed with
the nonspecific MCS-ac or in the absence
of DNA.
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FIG. 7. A, transcriptional response of transiently transfected LNCaP cells with the ARR3-luc reporter with either: ARNt, ARNt/DBD, ARDBD/LBD,
or empty vector (PRC-CMV). B, ARR3-luc response in transiently transfected LNCaP cells using ARWT and -catenin deletion constructs, including
-CatWT, -CatArm, -CatNt, and -CatCt. Cells were transfected with full-length -catenin with () or without () the presence of 10 nM R1881.
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upon addition of ligand, it is reasonable to assume that there is
dynamic subnuclear trafficking of these receptors. Focal accu-
mulations of nuclear proteins in androgen-treated cells likely
consist of transcriptionally active protein complexes with the
AR, -catenin, and other associated co-factors, including SRC,
CBP, and TCF4 being present. These studies are currently
being addressed. The co-localization of the AR and -catenin
was not exclusive as seen by confocal microscopy suggesting
that there are many AR complexes unoccupied by -catenin
and, similarly, -catenin complexes that are unoccupied by the
AR. The co-localization of -catenin with the AR also implies
that -catenin could be involved with the transcriptional ma-
chinery of LNCaP cells. This prospect was explored with the
use of a novel DNA binding assay. Using an acrydite polymer,
we were able to show specific AR-dependent binding of -cate-
nin to the probasin promoter. This suggests that -catenin
could have the capacity to modulate the cell cycle in prostate
cancer cells in an androgen-dependent fashion, likely by alter-
ing levels of downstream known AR-modulated transcription
factors such as c-myc (39) and the cyclins (40). It is probable
that -catenin regulates downstream transcription factors by
acting as an AR co-activator in a pro-survival manner. Simi-
larly, the AR could have an influence on the Wnt pathway as
other steroid receptors such as the RAR and TR have been
shown to repress the Wnt pathway. Such a ligand-dependent
interplay might suggest sharing of nuclear -catenin between
various promoter sites.
Steroid Receptor Nuclear Translocation of -Catenin by the
Androgen Receptor—AR-mediated translocation of -catenin
was considerable both with light level experiments and bio-
chemical data with the majority of migrating AR reaching the
nucleus by 60 min after the addition of ligand. Time-course
experiments extended beyond this time point (data not shown)
did not yield significant amounts of AR or -catenin movement
between compartments. In both endogenously expressed AR
cells (LNCaP) and transfected AR-expressing cells (PC3), time
series cell fractionations showed a modest, ligand-dependent,
nuclear translocation of -catenin. The movement of -catenin
was, in general, much less obvious in the cytosolic fraction. We
attribute this to the fact that the percentage of -catenin asso-
ciated with the AR and able to move to the nucleus is relatively
small compared with the total cytosolic pool of -catenin. Ad-
ditionally, it is likely that the amount of “free,” non-bound,
-catenin varies considerably between different cell lines. The
issue of different cytoplasmic pools of -catenin has been raised
in previous studies and could be functionally important in AR
transcription. Previous reports (41) have identified distinct
pools of catenins, which are suggestive of a balancing between
APC and AR interactive -catenin. It would be interesting to
evaluate how other cytoplasmic pathways are altered as a
function of the removal of androgen-associated -catenin upon
its nuclear translocation. Certainly, prior to an achieved equi-
librium of cellular -catenin, there would be perturbation to
the Wnt pathway and Wnt-associated transcription factors. An
equally interesting notion is the concept of different nuclear
compartments of -catenin of which are likely in a constant
state of flux as nuclear receptors and TCF4-related complexes
could trade off available -catenin.
Time series experiments showed relatively little, if any,
movement of ER between the cytosol and the nucleus. This
finding supports previous reports showing that the ER is found
predominantly in the nucleus with or without the presence of
ligand (22). Given that we did not detect nuclear translocation
of TR and RAR, the mechanism as to how -catenin augments
their transcriptional activity (42, 43) requires future investiga-
tion. Although we were not able to detect trafficking of -cate-
nin with these receptors, we cannot rule out the possibility that
during the initial translation and modification of these recep-
tors some -catenin is brought to the nucleus. Such a form of
Catenin trafficking would not be detectable with the tech-
niques used in this study. The finding that GR does not facili-
tate -catenin translocation in the same manner as AR does
could be a function of the cell lines used in the present studies;
that is, cells that express high levels of GR likely show a
greater ability to translocate -catenin as compared with pros-
tate cancer cell lines. Future studies using such cell lines will
help elucidate if a functional relationship exists between GR
and -catenin.
We sought to determine the minimally required components
for translocation of -catenin to the nucleus. By transiently
transfecting a series of deletion mutants into PC3 cells we able
to determine that -catenin requires the ARDBD region for
binding but requires the ARDBD/LBD for significant ligand-de-
pendent nuclear translocation. These observations are consist-
ent with previous reports describing the necessity of the ligand
binding domain for nuclear localization. -Catenin showed a
small degree of nuclear movement in cells that were ARNt/DBD-
transfected but not in prominent, ligand-dependent manner as
observed when cells were transfected with ARDBD/LBD. By GST
fusion protein interactions we determined that the ARDBD re-
gion is capable of a strong receptor/-catenin interaction with-
out the ARLBD indicating that minor amounts of -catenin,
although not detected by our methods, may be carried into the
nucleus by the ARDBD independent of the ARDBD. When we
examined the relative affinities between the AR and -catenin
as a function of the presence of ligand presence, we did not
observe any difference, likely due to the absence of chaperone
proteins that would otherwise mask binding. We further inves-
tigated what the minimal requirement of AR and -catenin
domains for nuclear translocation and found that ligand-de-
pendent movement could be achieved using transfected ARDBD/
LBD and the Arm repeats of -catenin. The Arm repeats of
-catenin are known binding sites for other molecules, includ-
FIG. 8. Proposed model showing that the androgen receptor
(AR) may facilitate translocation of cytoplasmic -catenin
(Cat) to the nucleus and thereby increase AR transcription
and possibly regulate Wnt. Upon ligand occupation heat-shock pro-
teins (Hsp) dissociate from the AR allowing for augmentation of -cate-
nin binding. Hsp dissociation also exposes the AR nuclear localization
site, which could promote translocation of an AR--catenin complex into
the nucleus and binding to one or more AR promoters.
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ing E-Cadherin, TCF, CBP, and fascin. The elucidation of the
exact region of Arm repeat binding to a region such as the DNA
binding domain of steroid receptors is currently being
investigated.
LNCaP and PC3 prostate cancer cells are in many respects
good systems to demonstrate the hypothesis of AR-mediated
nuclear translocation of -catenin. This is mainly due to con-
stitutively low activity of GSK-3 and highly active Akt (18), a
regulator of GSK-3. Irregular GSK-3 and Akt levels can be
attributed to the mutated tumor suppressor phosphatase with
tensin homology, which both cell types carry. Furthermore, the
relative amounts of unphosphorylated -catenin are likely
higher than other cell types where GSK-3 activity are at higher
endogenous levels implying that any additional cytosolic
-catenin could have the potential for other binding partners
such as cytosolic steroid receptors. By using tagged -catenin
constructs, we were more easily able to monitor the movement
of this exogenous -catenin. Western blotting for the tran-
siently transfected tagged -catenin showed a much more pro-
nounced translocation of -catenin, likely because the large
amount of endogenous -catenin, by our detection methods,
previously masked its movement. Although AR-dependent
movement of -catenin appears to be functional independent of
functional APC, the continual movement of -catenin from the
cytoplasm to the nucleus and back to the cytoplasm in cancer
cells suggests that these pathways can be functionally inde-
pendent but can also draw from similar pools of -catenin.
Our proposed model of AR mediated transport of -catenin
(Fig. 8) shows that upon ligand occupation heat-shock proteins
(Hsp) also dissociate from the AR allowing for augmentation of
-catenin binding. Hsp dissociation also exposes the AR nu-
clear localization site, which could promote translocation of an
AR--catenin complex into the nucleus and binding to one or
more AR promoters. Our finding of an AR-mediated trafficking
pathway leads to the logical implication for a role in oncogen-
esis whereby stimulation of the Wnt pathway could promote
greater cytosolic -catenin and therefore greater AR transcrip-
tional activity. Increased nuclear -catenin could result in al-
tered cell cycle or increased differentiation.
Future studies will likely include investigations of how the
AR and other nuclear receptors interact with the Wnt pathway.
With the high degree of conservation between the DNA binding
regions within the nuclear receptor family, it is likely that
there are many commonalities between the AR, GR, and ER
with respect to how they could influence Wnt-related genes as
a function of ligand exposure. Similarly, the ability of -catenin
to augment transcriptional activity of other nuclear receptors is
a significant finding and will likely lead to further studies in
specific tissues such as the thyroid-targeted tissues, breast and
liver. With the apparent similarities in how -catenin may
interact with the currently investigated nuclear receptors, it is
likely there are many caveats to how -catenin could influence
individual receptor pathways. Ultimately, such interactions
may lead to more invasive studies whereby repression of Wnt
members could attenuate steroid receptor associated transcrip-
tional activation. A key to elucidating how the Wnt pathway
interacts with nuclear receptors lies in understanding the
likely dynamic interplay between TCF components, nuclear
receptor promoters, and -catenin, but also shared co-factors
such as CBP and many, yet, undefined ones with the potential
to facilitate both pathways.
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